STC-15 is under clinical development by Storm Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STC-15’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STC-15 overview
STC-15 is under development for the treatment of acute myeloid leukaemia (AML) and other solid cancers. The drug candidate acts by targeting methyltransferase-like protein 3 (METTL3). It is administered through an oral route.
See Also:
Storm Therapeutics overview
Storm Therapeutics. (STORM) is a clinical-stage biotechnology company that discovers and develops novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. The company’s pipeline products include METTL3 (STC-15), ADARI (Exelixis) and UKRI. Its pipeline candidates treat oncology and, covid -19 viral infection. STORM is funded by M Ventures, Pfizer, Taiho Ventures, LLC, Seroba, Cambridge Innovation Capital, IP Group, The University of Tokyo IPC and Fast Track Initiative . Storm Therapeutics is headquartered in Cambridge, England, the UK.
For a complete picture of STC-15’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.